(Información remitida por la empresa firmante)
3. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly sensitized patients on the basis of acceptable HLA mismatches.) Available https://cordis.europa.eu/project/id/305385/reporting. 4. Redfield R, et al. Nephrol Dial Transplant 2016; 31:1746–1753
5. Lonze BE, et al. Ann Surg 2018; 268(3):488–496
6. EDQM. (2020). International figures on donation and Transplantation 2019
7. SRTR Database and individual assessments of allocation systems
8. European Medicines Agency. Idefirix summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf. Last accessed: May 2023
9. Jordan SC, et al. N Engl J Med 2017; 377(5):442-453.
10. Manook M, et al. Lancet 2017; 389(10070):727-734.
11. Winstedt L, et al. PLoS One 2015; 10(7): e0132011
12. Lorant T, et al. Am J Transplant 2018;18(11):2752-2762.
13. Jordan SC, et al. Transplantation October 21 2020 – volume online first issue
14. NIH (2018). What is kidney failure? Available at: https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure. Last accessed May 2021
15. Newsletter Transplant 2020. pp 58–60.
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-belgium-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation-301839629.html